The in vitro susceptibilities of Actinobacilus actinomycetemcomitans to 14 antimicrobial combinations were studied by using the checkerboard titration technique. The results, expressed as the range of the fractional inhibitory concentration indices, were as follows: for metronidazole or its hydroxymetabolite combined with cefixime, 0.2 to 0.6; for moxalactam, 0.2 to 0.6; for penicillin G, 0.3 to 0.6; for tobramycin, 0.8 to 2.0; for erythromycin, 0.8 to 1.7; for ciprofloxacin, 0.2 to 0.6; for tetracycline, 0.8 to 1.2. Our observations indicated that the 1-lactam antibiotics as well as ciprofloxacin act synergistically with both metronidazole and its hydroxymetabolite againstA. acinomycetemcomians. Synergistic interactions were independent ofthe individual MICs of the antibiotics tested. Erythromycin, tobramycin, and tetracycline combined with either metronidazole or its hydroxymetabolite showed additive to indifferent effects against the five strains ofA. actdnmycetemcomians, with the fractional inhibitory concentration indices ranging from 0.8 to 2.0. A. actinomycetemomitan was found to be hily susceptible to ciprofloxacin (MIC of ciprofloxacin for 90%o of strains tested, 0.010 p.g/ml) and cefixime (MIC of cefxime for 901% of strains tested, 0.8 ,ug/ml). The results indicate that in patients who are allergic to penicillin, cefixime and ciprofloxacin may be useful alternative antibiotics in combination with metronidazole for the treatment ofA. acdnomycetemcomians-associated periodontitis.
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Actinobacillus actinomycetemcomitans, a rod-shaped gram-negative coccobacillus, is a pathogen in several nonoral diseases (9, 13, 14, 21, 36 ) and a putative pathogen in periodontal disease (4, 7, 15, 25, 29, 30, 36) . Treatment ofA. actinomycetemcomitans-associated periodontitis by subgingival debridement has appeared ineffective with regard to eradication ofA. actinomycetemcomitans from the periodontal area (23, 24, 31) . For adequate treatment of this infection, antibiotics are required. In 1989, van Winkelhoff et al. (34) showed that mechanical treatment followed by a regimen of metronidazole and amoxicillin for 7 days is effective in eliminating A. actinomycetemcomitans from the infected sites. Recently, this was confirmed in a large patient group, in which more than 95% eradication of the microorganism was reported (35) . An explanation for the in vivo efficacy may be the in vitro synergism against A. actinomycetemcomitans not only between metronidazole and amoxicillin but also between metronidazole and its hydroxymetabolite as well as between amoxicillin and the hydroxymetabolite of metronidazole (20) . However, in some patients, effective treatment with the metronidazole-amoxicillin combination is contraindicated for several reasons; patients can suffer from serious adverse effects caused by amoxicillin, and patients can have allergies toward 3-lactam antibiotics. An alternative antibiotic therapy for these patients is still not available.
The aim of the study described here was to investigate the interactions between several antibiotic combinations by using the checkerboard titration technique (3) and A. actinomycetemcomitans as the test organism. The combinations tested were metronidazole and its hydroxymetabolite combined with cefixime, moxalactam, penicillin G, tobramycin, erythromycin, ciprofloxacin, and tetracycline. As a fol-* Corresponding author.
low-up to this study, the in vitro susceptibilities of 50 additionalA. actinomycetemcomitans strains to cefixime, an expanded-spectrum oral cephalosporin, and ciprofloxacin, a 4-fluoroquinolone, were assessed. As a result of the present study, ciprofloxacin and two new combinations, metronidazole combined with cefixime and metronidazole combined with ciprofloxacin, were tested for their abilities to eradicate A. actinomycetemcomitans from patients suffering from A. actinomycetemcomitans-associated periodontitis. Determination of FICIs. To specify the degree of interaction between the antibiotics, fractional inhibitory concentrations and fractional inhibitory concentration indices (FICIs) were calculated for the wells in which no visible growth could be detected. The criteria that one uses to decide whether a combination of antibiotics acts synergistically, additively, or antagonistically are based on the accuracy of the MIC determination (20) . Synergism in a two-dimensional checkerboard test is defined by FICIs of 50.5 by using twofold serial dilutions for the MIC determination (3) . A more exact understanding of the interactions between two antibiotics can be obtained by determining the precise MICs (20) . This can be achieved when smaller dilution steps are used. In the present study, the MICs were determined by using dilution steps of 10%. From this we deduced that synergism can be defined as FICIs of .0.7. This value is obtained mathematically by subtracting the sum of the maximal errors made in the MIC determinations (0.2) and the maximal errors made in the pipetting and diluting steps (0.1) from the theoretical FICI limit for synergism (1.0) (3).
MATERIALS AND METHODS
Pilot study on the effects of ciprofloxacin, metronidazole plus cefiime, and metronidazole plus ciprofloxacin in patients with A. actinomycetemcomitans-associated periodontitis. Two patients with A. actinomycetemcomitans periodontitis were treated by mechanical debridement of the periodontal pockets. This treatment was followed by treatment with a regimen of ciprofloxacin (500 mg twice daily for 7 days). Three patients were treated by mechanical debridement followed by a regi,men consisting of metronidazole plus cefixime (metronidazole, 500 mg twice daily; cefixime, 200 mg twice daily; both drugs were given for 7 days). Four patients with A. actinomycetemcomitans-associated periodontitis were treated by mechanical debridement followed by treatment with the combination of metronidazole plus ciprofloxacin (metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; both drugs were given for 7 days).
Samples for microbiological analysis were obtained with sterile paper points from four selected pockets which were positive for A. actinomycetemcomitans before treatment, pooled, and transported in reduced transport fluid to the laboratory (33) . From this pooled sample, 10-fold dilutions were prepared in reduced transport fluid and were plated onto selective TSBV plates for the detection of A. actinomycetemcomitans (28) . TSBV plates were incubated in a CO2 incubator (5% CO2 in air). A. actinomycetemcomitans was identified on the basis of its specific colony morphology on TSBV plates (star-like inner structure) and the production of catalase and other specific enzymes (27) . RESULTS For 50 A. actinomycetemcomitans strains, the MICs of cefixime and ciprofloxacin for 90% of strains tested under both anaerobic and microaerophilic culture conditions were 0.8 ,g/ml (range, 0.3 to 2.2 p,g/ml) and 0.010 ,g/ml (range, 0.001 to 0.020 pg/ml), respectively. All strains were susceptible to both antibiotics. No difference in the MIC of either antibiotic was observed under either culture condition. The MICs of metronidazole, its hydroxymetabolite, cefixime, moxalactam, penicillin G, ciprofloxacin, erythromycin, tetracycline, and tobramycin for the five A. actinomycetemcomitans strains used in the checkerboard titration experiments are listed in Table 1 . The MIC for each strain was determined twice in duplicate, and the MICs showed little variation. The five A. actinomycetemcomitans strains were susceptible to cefixime, penicillin G (except strain HG 1178), ciprofloxacin, tetracycline, tobramycin, and the hydroxymetabolite of metronidazole; but they were less susceptible to moxalactam, erythromycin, and metronidazole. The results of the checkerboard titrations are listed in Table 2 . All checkerboard titrations showed a variation in the FICI of no more than 0.1 for each strain. The FICIs of all antibiotic combinations listed in Table 2 are the sum of the two lowest fractional inhibitory concentrations determined for each combination per strain. Metronidazole or its hydroxymetabolite combined with cefixime, penicillin G, moxalactam, or ciprofloxacin had FICIs less than or equal to 0.6 (range, from 0.2 to 0.6), indicating synergistic interactions. Synergy did not depend on the susceptibilities of the A. actinomycetemcomitans strains to the compounds when the compounds were used separately but was observed for all strains.
The nature of the interaction between metronidazole or its hydroxymetabolite and tetracycline, erythromycin, and tobramycin can be described as additive to indifferent, with FICIs ranging from 0.8 to 2.0.
The results of the clinical pilot study showed that a therapy consisting of mechanical debridement followed by a regimen of ciprofloxacin alone was ineffective in eliminating A. actinomycetemcomitans from the periodontal pockets in two patients. The two synergistically acting combinations, metronidazole plus cefixime and metronidazole plus ciprofloxacin, were tested for their ability to eradicate A. actinomycetemcomitans from the periodontal lesions in three and four patients, respectively. The results of the pilot study indicated that mechanical therapy followed by treatment VOL. 36, 1992 with either one of the two combinations suppresses A. synergistic effects between metronidazole, its hydroxymeactinomycetemcomitans at the site of infection for at least 3 tabolite, and ,B-lactam antibiotics is still unclear. It is possimonths.
ble that the inhibition of peptidoglycan synthesis by ,-lactam antibiotics causes an enhanced influx of metronidazole and DISCUSSION its hydroxymetabolite, leading to faster bactericidal activity. We found it striking that synergistic interactions between the The results of a previous study showed that metronidaf-lactam antibiotics, metronidazole, and its hydroxymetabzole, its hydroxymetabolite, and amoxicillin act synergistiolite were also present among the strains which were relacally againstA. actinomycetemcomitans (20) . The aim of the tively less susceptible to penicillin G (strain HG 1178) and present study was to investigate the interactions between moxalactam (all strains). The synergistic interactions bemetronidazole, its hydroxymetabolite, and a set of antibiottween ciprofloxacin and metronidazole and ciprofloxacin ics belonging to different groups by using A. actinomycetand the hydroxymetabolite of metronidazole are also not emcomitans as the test organism. A marked result of the understood. The mode of action of ciprofloxacin is inhibition study is that only the 1-lactams penicillin G, moxalactam, of bacterial DNA gyrase activity (8) .
and cefixime and the 4-fluoroquinolone ciprofloxacin act The results of the pilot study on the effects of ciprofloxacin synergistically with metronidazole and its hydroxymetaboindicate that the high, in vitro activity of ciprofloxacin against lite. Interactions between the hydroxymetabolite and other A. actinomycetemcomitans (MIC for 90% of strains tested, antibiotics were studied because A. actinomycetemcomitans 0.010 ,ug/ml) does not correlate with the in vivo outcome, is two to four times more susceptible to this compound than since a therapy consisting of mechanical debridement folit is to metronidazole and because of its synergistic interaclowed by a treatment regimen with ciprofloxacin alone was tion with metronidazole and amoxicillin (12, 20, 31) . Also, its ineffective in eliminating A. actinomycetemcomitans from concentrations in human serum, crevicular fluid, and saliva the periodontal pockets. However, the results of the pilot are comparable to those of metronidazole in the same human study on the effects of metronidazole plus cefixime and fluids (10) , which indicates that the hydroxymetabolite probmetronidazole plus ciprofloxacin indicate that in vitro synably contributes significantly to the effectiveness of the ergy between metronidazole, its hydroxymetabolite, and metronidazole-amoxicillin combination. The nature of the cefixime and ciprofloxacin may have a predictive value for The results of previous studies (5, 11, 15, 18, 26, 31, 32, 34, 35) and the results of our pilot study suggest that eradication ofA. actinomycetemcomitans is predictable when combinations of antibiotics show in vitro synergism.
Several studies on treatment strategies for some infectious diseases suggest that they also require that patients be treated with double or even triple antimicrobial combinations rather than a monotherapy. This seems to be true for pelvic inflammatory disease (6) and Helicobacter pylonassociated gastritis (19, 22) . Also, A. actinomycetemcomitans-associated periodontitis and possibly all other infections caused by this microorganism, e.g., endocarditis (9, 13, 14, 22) , must be added to the list of infectious diseases that cannot be treated effectively with antimicrobial monotherapies. It is likely that the bacteria involved in such diseases are located in areas where most antibiotics do not reach levels that exceed concentrations greater than the MIC or that the availability of the drug is too low (17) . In such cases, therapy mostly fails. However, synergistic interactions between antibiotics can probably solve the problem of low antibiotic concentrations or drug availability at the site of infection. Infective endocarditis caused by A. actinomycetemcomitans is mostly treated with antibiotic combinations consisting of a 1-lactam combined with either gentamicin or tobramycin (9, 13, 14, 21) . The choice of combinations of antibiotics for the treatment of A. actinomycetemcomitans infections, such as infective endocarditis, is seldom based on in vitro synergistic interactions between the antibiotics. Moreover, the literature on the in vitro interactions between those antibiotic combinations provides only little information about the nature of the interactions (9, 13, 14, 21) . The results of the present and previous studies (20, 34, 35) indicate that synergistically acting antibiotic combinations, i.e., metronidazole plus amoxicillin, metronidazole plus cefixime, and metronidazole plus ciprofloxacin, may be useful in the treatment of A. actinomycetemcomitans infections such as A. actinomycetemcomitans-associated periodontitis and infective endocarditis. In conclusion, the in vitro synergism between metronidazole, its hydroxymetabolite, and additional antibiotics may be a useful predictor of therapeutic efficacy in the treatment of patients with A. actinomycetemcomitans-associated periodontitis and possibly other infections caused by A. actinomycetemcomitans.
